Related Experiment Video

Updated: Apr 17, 2026

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy
03:57

Generation of Hypoparathyroid Rats via Carbon-Nanoparticle-Assisted Parathyroidectomy

Published on: July 14, 2023

2.5K

Homoarginine in patients with primary hyperparathyroidism

Andreas Tomaschitz1, Nicolas Verheyen, Martin Gaksch

  • 1Department of Cardiology (AT, NV, BP, EK-K, CC, AS, EB), Medical University of Graz, Graz, Austria; Specialist Clinic for Rehabilitation PV Bad Aussee (AT, JR-M), Bad Aussee, Austria; Medizinische Klinik mit Schwerpunkt Kardiologie (AT, BP, EK-K), Campus Virchow-Klinikum, Charité-Universitaetsmedizin Berlin, Berlin, Germany; Division of Endocrinology and Metabolism, Department of Internal Medicine (MG, CS, KA, AF-P, SP), Medical University of Graz, Graz, Austria; Clinical Institute of Medical and Chemical Laboratory Diagnostics (AM, WM), Medical University of Graz, Graz, Austria; Synlab-Academy (WM), Synlab services LLC, Mannheim, Germany; Medical Clinic V (Nephrology, Hypertensiology, Endocrinology, Diabetology, Rheumatology) (WM), Ruperto Carola University Heidelberg, Medical Faculty Mannheim, Mannheim, Germany; Department of Epidemiology and Biostatistics (AJvB) and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands; and Department of Medicine, Division of Nephrology (ER), University Hospital Heidelberg, Heidelberg, Germany.

The American Journal of the Medical Sciences
|February 4, 2015
PubMed
Summary

Patients with primary hyperparathyroidism (PHPT) have lower levels of the amino acid homoarginine. This finding suggests a potential link between excess parathyroid hormone (PTH) and cardiovascular risk factors.

More Related Videos

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation07:13

Two Techniques to Create Hypoparathyroid Mice: Parathyroidectomy Using GFP Glands and Diphtheria-Toxin-Mediated Parathyroid Ablation

Published on: March 14, 2017

15.5K
Procurement of Parathyroid Glands from Living Donor Pigs and Ex Vivo Identification08:07

Procurement of Parathyroid Glands from Living Donor Pigs and Ex Vivo Identification

Published on: August 1, 2025

1.3K

Related Concept Videos

The Parathyroid Glands00:59

The Parathyroid Glands

The two pairs of parathyroid glands embedded within the posterior surface of the thyroid gland are restricted by a dense capsule around them. These glands comprise two distinct cell populations—parathyroid oxyphil and parathyroid principal cells- pivotal in calcium homeostasis.
Oxyphil cells, whose functions remain elusive, emerge during late puberty, adding a layer of complexity to the parathyroid gland's intricacies. In contrast, principal parathyroid cells undertake a vital role by...
6.2K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
4.3K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
789
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
667
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
623
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
6